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was irradiated receiving 50,4 Gy. The comorbidities 
associated were: 21% diabetes, 62,5% High blood pressure, 
40% cardiac pathology and 33 % were with anticoagulant 
treatment. All our haematuria patients have been handled 
following the next algorithm: Blood Test (Including platelets 
and liver parameters) and Urine Culture. If both are negative: 
Ultrasound (Kydney, urether and bladder). If haematuria goes 
on: Cystoscopy. 
 
Results: With a median follow-up of 52.5 months (range 5-
122 m), 48 patients (13%) have had haematuria. As etiological 
factors we have been found: Urine Infection 12 p (25%. Time 
32 months (12-70 m), Bladder cáncer 10 p (21%. Four of them 
a recurrence of a previous treated bladder tumour. Time: 32 
months (3-120 m), RADIATION CYSTITIS 10 p (21%. Time: 13 
months (6 – 38 m), Lithiasis 4 p (8%. Time: 25.5 months (26-
30 m), Local progression of Prostate cancer 1 p (2%). Time: 
72 months), Autolimited haematuria (Culture and image 
studies negatives. It does not repeat.): 9 p (19%. Time: 58 
months (25-80 m) and Fatal haematuria (Exitus. Not known 
etiology): 2 p (4%. Time: 78 and 84 months). 
 
Conclusion: In our experience, haematuria is a frecuent 
pathology in patients treated with radiotherapy of prostate 
cancer. The etiology of it spreading in similar proportions, 
across the different causes founded. The time of it 
presentation is important for the diagnostic. In the mind of 
the specialist must be different causes of it, NOT ONLY 
radiotherapy Cystitis taking in account that if it is due to 
radiotherapy it appears mainly, in the first two years after 
radiotherapy treatment. 
 
EP-1339  
Influence of leaf thickness on prostate VMAT about 
dosimeto-volumetoric and delivering parameters 
H. Nagano
1Shonan Fujisawa Tokushukai Hospital, Radiation Oncology 
Department, Fujisawa, Japan 
1, H. Yokoyama1, H. Hashimoto1, M. Watanabe1, M. 
Nakanishi1, Y. Kishida1, T. Ogawa1, T. Kawasaki1, M. Katou2, 
T. Shimo2, K. Ishizuka1 
2Tokyo West Tokushukai Hospital, Radiation Oncology 
Department, Tokyo, Japan 
 
Purpose or Objective: Volumetric modulated arc therapy 
(VMAT), a complex treatment strategy for intensity-
modulated radiation therapy, has been established clinically. 
While 5 mm thick MLC (L50) is a usual for VMAT, we have 
been using 2.5 mm thick MLC (L25) from 2012 to treat the 
prostate cancer. So we compared dosimetric, volumetric and 
dose delivering parameters between L25 and L50. 
 
Material and Methods: Twenty four cases were selected from 
our database. Those patients were treated for the prostate 
carcinoma in the feet-first prone position. Gantry angle range 
was 182 deg. to 178 deg. and collimation angle was set 0 deg. 
SmartArc system of Pinnacle3 was used with 6MVX physical 
data of Novalis Tx (L25) and 6MVX Siemens® ARTISTE 
physical data loaded on Varian Clinac-21 Ex (the base 
machine of Novalis) virtually (L50). The same consolidations 
for optimization were used. For example, Min Dose, D95 and 
Max Dose of PTV were 76 Gy, 80 Gy and 84 Gy, respectively. 
Rectal V40 was set to 20%. Wilcoxon rank sum test was 
applied to D98, D95, D50 and D02 of PTV, rectal V40, 
irradiation time and MU. To analyze relationships between 
these values and ROV grouped by L25 or L50, linear 
regression model was employed with analysis of covariance 
for the regression coefficients.  
 
Results: Mean values of D98, D95, D50 and D02, V40, Time 
and MU were 75.8 Gy, 77.5 Gy, 81.2 Gy, 84.2 Gy, 20.3%, 82.7 
sec and 646.6 for L25, and were 75.6 Gy, 77.3 Gy, 81.0 Gy, 
83.8 Gy, 19.6 %, 149.9 sec and 741.6 for L50, respectively. 
Only those mean values of D02, V40 and Time were 
significantly different between L25 and L50 by Wilcoxon test 
(Table). 
 
 
D98, D95, V40, Time and MU depended on ROV significantly. 
Slopes of valuables grouped by L25 and L50 were very similar 
in the all except Time and MU (Table and Figure). 
 
 
 
Conclusion: L25 and L50 plans were very similar from the 
dosimetric point of view (difference of D02 was significant 
but very small in value; 0.4Gy, L25>L50). From the 
volumetric (V40) point of view, difference was small (0.7%, 
L25>L50) but significant. In terms of dose delivery (Time), 
differences were remarkable and largely depend on the ROV 
especially in the cases of L50. We may use L50 with the 
expense of treatment time compared to L25. 
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Purpose or Objective: For patients with clinically localized 
prostate cancer with high probabilities to undergo adjuvant 
radiotherapy after radical prostatectomy(RP), radical 
radiotherapy may be a proper treatment option for saving 
time and medical costs. Our purpose is to develop 
nomograms combining PSA level, clinical T stage, and biopsy 
Gleason Score to predict probabilities of having indications 
for adjuvant radiotherapy including extraprostatic extension, 
positive margin, Gleason Score 8-10 and to provide data for 
individualizing initial treatment options. 
 
Material and Methods: We analyzed 214 men treated with RP 
between August 2013 and August 2015 at our hospital. 
Average age was 66 years. Men who enrolled in this study had 
a preoperative PSA level assessed before or at least 4 weeks 
after prostate biopsy, biopsy Gleason Score, pelvic MRI and 
clinical T stage (TNM 2009 classification). Men were excluded 
for preoperative treatment with neoadjuvant hormonal 
therapy, or transurethral resection of the prostate because of 
potential influence on pathologic stage or PSA level. 
Preoperative predictors included PSA level, clinical T stage 
(T2a/b, T2c, T3a, T3b), and biopsy Gleason score (5-6, 
3+4=7, 4+3=7, 8-10). These predictors were used in 
multivariable logistic regression analysis based nomograms to 
estimate the probabilities of extraprostatic extension, 
positive margin, Gleason Score 8-10 after RP, respectively. 
The predictive accuracy and discriminative ability of the 
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nomogram were determined by concordance index(C-index) 
and calibration curve. 
 
Results: 47% of the patients had extraprostatic extension, 
36% had positive margin, and 20% had Gleason Score 8-10. 
Nomograms were developed for the predicted probabilities of 
having the indications of adjuvant radiation 
therapy(Fig1ABC). The calibration curve for probabilities 
showed good agreement between prediction by nomogram 
and actual observation (Fig 1DEF). The C-index of the 
nomograms for predicting extraprostatic extension disease, 
positive margin, and Gleason Score 8-10 were 0.799, 0.746, 
0.879, respectively. The risk of having one of the indications 
of adjuvant radiation therapy increased with increases in 
predictors except for T stage for predicting Gleason Score 8-
10(p=0.25). 
 
 
Fig.1 nomograms and calibration curves 
 
Conclusion: We produced nomograms that may accurately 
predict the probabilities of having indications for adjuvant 
radiation therapy after RP in men with localized prostate 
cancer, which may contributes to properly selecting initial 
treatment option. 
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Purpose or Objective: Together with surgery, radiotherapy 
(RT) is a cornerstone in the treatment of prostate cancer. 
Despite similar prognostic factors, a wide inter-patient 
variability was observed in tumour response and side effects. 
Many studies have been made to understand molecular 
behaviour of tumours exposed to ionizing radiation. It has 
been hypothesized that single-nucleotide polymorphisms 
(SNPs) impact response and adverse reactions for patients 
(pts) receiving RT. We focused on the analysis of some 
candidate SNPs in pts treated with RT for prostate cancer. 
 
Material and Methods: Between January and September 
2014, 66 pts with prostate cancer underwent RT with radical 
or adjuvant intent. RT was delivered using 4-6 coplanar 10-18 
MV beams at a dose of 70-80 Gy (2.5-2 Gy/fraction). At 
baseline and weekly during treatment, acute gastrointestinal 
(GI) and genitourinary (GU) toxicities were scored by a fixed 
questionnaire. The RTOG toxicity scale served as a basis, but 
additional symptoms were evaluated as well. Genotyping was 
performed from whole blood samples at the beginning of RT. 
DNA was purified with the QIAamp DNA Mini Kit. Assays of 
samples were performed using the “Radiotherapy response” 
kit (Diatech Pharmacogenetics, Italy). Pyrosequencing 
analysis was carried on the PyroMark Q96 ID (Biotage, 
Sweden). Status of candidate SNPs (GSTP1 A313G, RAD51 
G135C, XRCC1 G28152A, XRCC3 A4541G and XRCC3 C18067T) 
was unknown to interviewers and participants. 
 
Results: Treatments were delivered successfully without any 
interruption. Grade 1, Grade 2 and Grade 3 GI toxicities were 
observed in 33%, 12% and 3% of the pts, respectively, during 
the whole period. Grade 1, Grade 2 and Grade 3 GU toxicities 
were seen in 50%, 32% and 15% of the pts. Eight items of GI 
toxicity and six items of GU toxicity were used to calculate, 
for each patient, his own toxicity score. Time of onset of side 
effects was taken into account too. Using R statistical 
program, no significant relation was found between total 
toxicity or precocity of side effects and the mutational status 
of our 5 candidate loci, except for GSTP1 and toxicity. 
Kruskal-Wallis test demonstrated that GSTP1 status (wild-
type, heterozygous and mutant) is a strong predictor of GI 
effects, especially diarrhea (p=0.01), frequency of stools 
(p=0.01), incontinence (p=0.01) and rectal blood loss 
(p=0.02). 
 
Conclusion: Overall, RT is a well tolerated therapy for 
prostate cancer. Five SNPs were analyzed in four genes of 
relevance for RT. GSTP1 showed to be the most important 
SNP regarding GI toxicity to RT in pts treated for prostate 
cancer. Other examined SNPs did not prove to play a 
significant role in this particular subset of pts. Our findings 
require validation in larger replication studies and open to 
future clinical trials. One of the next steps will be evaluate if 
GSPT1 is associated with response to RT too. This would 
permit personalization and optimization of RT for each 
prostate cancer patient. 
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Purpose or Objective: To describe the F-18Fluorocholine 
PET/CT (cPET/TC) activity after biochemical failure in 
localized prostate cancer. To analyze the response to 
cPET/TC-guided salvage therapy. 
 
Material and Methods: N: 80 patients(p) with cPET/TC 
between 2006-2012, 64p at time of biochemical failure. 
At diagnosis 15p T1 (18.5%), 37p T2 (46.4%), 23p T3 (28.8%) 
and 5p T4 (6.3%). N0 (87.5%). Gleason score: 6: 30p (37.6%), 
7: 27p (33.8%),≥ 8: 20p (25.1%), missing: 3p (3.8%). Baseline 
median PSA 9.0 ng/ml. [0.9-114.5]  
Initial treatment: 45p (56.4%) prostatectomy, 13p (16.3%) 
radiotherapy and hormones 2.5 years, 11p (13.8%) 
radiotherapy and hormones 6 months, 7p (8.8%) radiotherapy 
alone and 4p (5%) had hormones alone. 
cPET/TC -guided salvage treatments were: 23 radiotherapy 
(36%), 2 brachytherapy (3.1%), 8 radiotherapy and hormones 
(12.5%), 29 hormones (45.3%), 1 chemotherapy (1.6%) and 1 
radical protatectomy (1.6%). 
 
Results: Median time from diagnosis to cPET/TC failure: 
44.03 months [2.37-126.83]. Median PSA values were 1.69 
ng/ml [0.1-70.6]. 
cPET/TC local failure(LF) occurred in 39p (60.9%), nodal 
failure(NF) in 15p (23.4%) and metastasic failure(MF) in 10p 
(15.6%).  
With a median follow up of 55 m after rescue treatment, 15p 
(23.4%) had biochemical failure again. At 5 years biochemical 
relapse free survival (BRFS) was 65%. Overall survival 5y: 91% 
(median: 119 months). 
BRFS was 59% without LF vs 83% with LF (p 0.26) 
BRFS was 75% without NF vs 30% with NF (p 0.065) 
